Department of Hematology, The Third Hospital of Mianyang, Sichuan Mental Health Center, Mianyang, China.
Department of General Surgery, The Third Hospital of Mianyang, Sichuan Mental Health Center, Mianyang, China.
Front Immunol. 2022 Jul 15;13:895961. doi: 10.3389/fimmu.2022.895961. eCollection 2022.
Chromosome instability (CIN) and its major consequence, aneuploidy, are hallmarks of human cancers. In addition to imposing fitness costs on tumor cells through several cell-intrinsic mechanisms, CIN/aneuploidy also provokes an antitumor immune response. However, as the major contributor to genomic instability, intratumor heterogeneity generated by CIN/aneuploidy helps tumor cells to evolve methods to overcome the antitumor role of the immune system or even convert the immune system to be tumor-promoting. Although the interplay between CIN/aneuploidy and the immune system is complex and context-dependent, understanding this interplay is essential for the success of immunotherapy in tumors exhibiting CIN/aneuploidy, regardless of whether the efficacy of immunotherapy is increased by combination with strategies to promote CIN/aneuploidy or by designing immunotherapies to target CIN/aneuploidy directly.
染色体不稳定性（CIN）及其主要后果——非整倍体，是人类癌症的特征。除了通过几种细胞内在机制给肿瘤细胞带来适应性代价外，CIN/非整倍体还会引发抗肿瘤免疫反应。然而，作为基因组不稳定性的主要贡献者，CIN/非整倍体产生的肿瘤内异质性有助于肿瘤细胞进化出克服免疫系统抗肿瘤作用的方法，甚至将免疫系统转化为促进肿瘤的作用。尽管 CIN/非整倍体与免疫系统之间的相互作用是复杂且依赖于背景的，但理解这种相互作用对于 CIN/非整倍体肿瘤的免疫治疗的成功至关重要，无论免疫疗法的疗效是通过与促进 CIN/非整倍体的策略联合使用来提高，还是通过设计针对 CIN/非整倍体的免疫疗法来提高。
